SCHEMBL1854867

SCHEMBL1854867

CC1(C)CC=C(c2cc(C3CNC(=N[N+](=O)[O-])NC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1

nearest known ligand 0.54

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 11/20 0.54
KIT P10721 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12421987 0.91 CSF1R (0.57) CSF1RKIT
SCHEMBL12482297 0.90 CSF1R (0.56) CSF1RKIT
SCHEMBL1859038 0.89 CSF1R (0.54) CSF1RKIT
SCHEMBL12408329 0.87 CSF1R (0.48) CSF1R
SCHEMBL3165017 0.84 CSF1R (0.58) CSF1RKIT
SCHEMBL1864639 0.84 CSF1R (0.74) CSF1RKIT
SCHEMBL19264442 0.84 CSF1R (0.56) CSF1RKIT
SCHEMBL4231011 0.83 CSF1R (0.57) CSF1RKIT
SCHEMBL1860359 0.83 CSF1R (0.74) CSF1RKIT
SCHEMBL14384614 0.83 CSF1R (0.57) CSF1RKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296726-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-03-29 US disclosed
US-20150051196-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2015-02-19 US disclosed
US-8895584-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2014-11-25 US disclosed
US-20140243382-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-08-28 US disclosed
US-8759347-B2 Inhibitors of C-FMS kinase JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 US disclosed
US-20130281475-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2013-10-24 US disclosed
US-8481564-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2013-07-09 US disclosed
US-20110195960-A1 INHIBITORS OF C-FMS KINASE ILLIG CARL R 2011-08-11 US disclosed
US-7973035-B2 Inhibitors of C-FMS kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2011-07-05 US disclosed
EP-2021335-B1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2011-05-25 EP disclosed
EP-2021335-B1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2011-05-25 EP disclosed
WO-2007124316-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 WO disclosed
US-20070249593-A1 e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281475-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES CSF1R 59/4885KIT 108/4885
US-20070249593-A1 e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent MUSK, CHUK, PNCK CSF1R 249/4885KIT 119/4885
US-20150051196-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES CSF1R 59/4885KIT 108/4885
US-20140243382-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES CSF1R 59/4885KIT 108/4885
US-20110195960-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES CSF1R 59/4885KIT 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.